What Kimyrsa treats.
- Acute bacterial skin and skin structure infections (ABSSSI)
- Cellulitis
- Wound infections
- MRSA infections
The mechanism.
Kimyrsa (oritavancin) is a lipoglycopeptide antibiotic that targets gram-positive bacteria including MRSA, MSSA, and streptococcal species. Like Dalvance, its long half-life allows a complete treatment course in a single dose. Kimyrsa is the newer, faster-infusion formulation of oritavancin (the older formulation, Orbactiv, is also available).
Your Kimyrsa infusion experience.
Kimyrsa is administered as a 1-hour IV infusion. One dose. That’s the entire antibiotic course for most skin and soft tissue infections. After your infusion you go home and resume normal activities. Compared to a traditional 7- to 14-day course of IV antibiotics, Kimyrsa is a substantial convenience and cost advantage.
Insurance & out-of-pocket cost.
Kimyrsa is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.